Comparing Antipsychotic Medications in LBD Over Time
Recruiting now · Phase 4
Conditions studied: Parkinson's Disease Psychosis, Dementia With Lewy Bodies
In brief
The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).
Key facts
- Study ID
- NCT05590637
- Run by
- The University of Texas Health Science Center at San Antonio
- People needed
- 94
- Starts
- 2022-04-22
- Expected to finish
- 2027-02-01
- Last updated by the study team
- 2025-09-09
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients seen in the neurology clinic at UT Health San Antonio
- Diagnosed with psychosis due to PD or DLB
- Requiring initiation of an antipsychotic medication
- Clinical equipoise between quetiapine and pimavanserin must exist
- The prescribing provider must be comfortable prescribing and managing both quetiapine and pimavanserin
You may not qualify if…
- Medical contraindication to either medication
- Caregiver unavailable to complete NPI-Q
- Currently taking an antipsychotic medication
- Prescribing provider unwilling to manage either medication
Where it is running
- University Health System — San Antonio, Texas, United States (enrolling)
- UT Health Science Center - San Antonio — San Antonio, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.